New hope for breast cancer survivors: trial tests vaginal treatments for hormone therapy side effects

NCT ID NCT05562518

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests four different vaginal treatments (estrogen, DHEA, estrogen with probiotics, and a moisturizer) in 160 breast cancer patients who have vaginal atrophy due to hormone therapy. The goal is to see which treatment best relieves symptoms like dryness and pain, and improves quality of life, while monitoring hormone levels for safety. Participants will use the treatments for 12 weeks, and their symptoms and vaginal health will be tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Estrogen, dehydroepiandrosterone (DHEA), probiotics, and moisturizer
What this could lead to
If successful, this trial could identify safe and effective local treatments for vaginal atrophy in breast cancer survivors, improving their comfort and quality of life.
What could go wrong
This is a phase 4 trial with a moderate size (160 participants). The treatments are already approved for other uses, but their safety and effectiveness in this specific group are still being studied. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Ghent

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.